Sandbox adult CHD complications
Template:Cardiogenic Shock - 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Arzu Kalayci, M.D. [2]
==AHA SCIENTIFIC STATEMENT - 2017== AHA
Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease
Advantages and Disadvantages of Imaging Modalities for Detection of Liver Disease and Screening for HCC in Patients With Congenital Heart Disease(CHD)
| Advantages | Disadvantages | Additional Notes | |
|---|---|---|---|
| Ultrasound | Inexpensive; Widely available; Highly sensitive for differentiating cystic and solid lesions; No ionising radiation | Low sensitivity for detecting focal, solid liver lesions, particularly in the setting of diffuse disease; Often unable to detect lesions <1 cm in size Low specs city; High operator dependency | Use of contrast agents may improve characterization of hepatic tutors; Useful for guiding liver parenchymal and some focal mass biopsies; Elastography may overestimate degree of brosis and may not be useful for screening in CHD |
| CT | Best spatial resolution (submillimeter resolution) | Exposure to ionizing radiation dose; Low sensitivity for detecting and characterizing lesions <1 cm in size; Contrast contraindicated in renal failure; Diffuse liver disease and fatty in ltration limit sensitivity for lesion detection | CT-guided liver mass biopsy useful in cases when ultrasound visualization is poor |
| MRI | High lesion-to-liver contrast High spatial resolution; Better lesion detection and characterization than CT; No ionising radiation; Unenhanced MRI superior to unenhanced CT | Contrast relatively contraindicated in renal failure (eGFR <30 mL·min−1·1.73 m−2); High cost; Long scan time; Need for longer breath-holds Less widely available; Unable to be used with many pacemakers and de brillators | Hepatobiliary contrast media useful in characterizing speci c liver tutors |
| CHD indicates congenital heart disease; CT, computed tomography; eGFR, estimated glomerular ltration rate; HCC, hepatocellular carcinoma; and MRI, magnetic resonance imaging. | |||